Background Image
Table of Contents Table of Contents
Previous Page  69 / 132 Next Page
Show Menu
Previous Page 69 / 132 Next Page
Page Background

2015 Annual Report


Risk Assessment

Management and

Research Outcomes





Laboratory and

Testing Network

Risk Communication

and Consumer



Cooperation and

Cross-Strait Exchange






Policy and








c. Regular and For Cause Inspection

Inspections were carried out regularly at manufacturing plants. For cause inspections were also

carried out where there are major quality concerns for the medicinal product.

d. Communicating Medicinal Product Risks

Medicinal product safety or quality alerts are publicly announced where necessary to remind

the general public and medical staff. In 2014, a total of nine press articles, 12 medicinal product

safety information and risk communication forms, recall information for 105 medicinal products,

and four Drug Safety Newsletters (on quarterly journals) were released.

e. Promoting Medicinal Product Risk Management amongst Pharmaceutical Companies

From 2010 onward ,the system of Medicinal Product Risk Management Plans for Pharmaceutical

Companies was gradually established for medicinal products with specific risk concerns.

Pharmaceutical companies and medical institutions are required to work together in order to

implement various risk control tools such as patient drug usage instructions, medical staff notification,

and special preventive measures. Follow-up assessments of implementation effectiveness are

also carried out regularly to ensure the public's drug use safety. Risk management is required for

diabetic medication that include Pioglitazone or Rosiglitazone, anti-epileptic drugs that contain

Carbamazepine, and medication that include TNF-alpha blockers.

(3) Training Risk Assessment Professionals

TFDA continued to provide training, seminars, and public announcements for medical staff,

pharmaceutical companies, and the general public on the topics of adverse reaction reporting,

defective product reporting, post-market surveillance and risk management for medicinal products.

In 2014, a total of nine seminars were held in order to improve understanding of medicinal product

management, compliance with reporting requirements amongst medical workers, and raise awareness

on the responsibilities for conducting post-market safety and quality surveillance and risk management

amongst pharmaceutical companies.

3. Medical Device Safety and Risk Assessments

(1) Risk Identification and Data Collection

a. Monitoring of Medical Device Alerts

In 2014, TFDA conducted continuous monitoring of medical device safety and quality incidents

posted on various official health websites on a daily basis. Information acquired from the monitoring

was also used to initiate domestic investigation. In 2014, a total of 3,058 alert-related operations

were monitored and filed accordingly.

b. Medical Device Adverse Reaction/Defect Report

In 2014, TFDA continuous received adverse reaction and defective product reports for medical

devices. These cases were then standardized for further analysis and evaluation. In 2014, a total of

209 domestic adverse reaction reports, 544 global adverse reaction reports, 1,401 defective product

reports, 181 clinical trial adverse reaction/defective product reports, and 102 periodic safety reports

were handled by TFDA.